Evidence map›Paper›PMID 38796759›Full record

ReviewProblemy endokrinologii2023

[Metastatic risk factors in pheochromocytoma/paraganglioma].

D V Rebrova, O I Loginova, S L Vorobyev, N V Vorokhobina, E S Kozorezova, F A Indeykin, T V Savelyeva, I V Sleptsov, R A Chernikov, E A Fedorov and 6 more

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Problemy endokrinologii, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

D V RebrovaSaint Petersburg State University, Saint Petersburg State University Hospital.
O I LoginovaSaint Petersburg State University, Saint Petersburg State University Hospital.
S L VorobyevNational Clinical Center of Morphological Diagnostic.
N V VorokhobinaNorth-Western State Medical University n.a. I.I. Mechnikov.
E S KozorezovaNational Clinical Center of Morphological Diagnostic.
F A IndeykinNational Clinical Center of Morphological Diagnostic.
T V SavelyevaSaint Petersburg State University, Saint Petersburg State University Hospital.
I V SleptsovSaint Petersburg State University, Saint Petersburg State University Hospital.
R A ChernikovSaint Petersburg State University, Saint Petersburg State University Hospital.
E A FedorovSaint Petersburg State University, Saint Petersburg State University Hospital.
A A SemenovSaint Petersburg State University, Saint Petersburg State University Hospital.
I K ChinchukSaint Petersburg State University, Saint Petersburg State University Hospital.
Sh Sh ShikhmagomedovSaint Petersburg State University, Saint Petersburg State University Hospital.
M A AlekseevSaint Petersburg State University, Saint Petersburg State University Hospital.
L M KrasnovSaint Petersburg State University, Saint Petersburg State University Hospital.
V F RusakovSaint Petersburg State University, Saint Petersburg State University Hospital.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, all pheochromocytoma/paraganglioma (PPGLs) are considered malignant due to metastatic potential. Consequently, PPGLs are divided into «metastatic» and «non-metastatic». Metastatic PPGLs can be with synchronous metastasis (metastases appear simultaneously with the identified primary tumor) or metachronous (metastases develop after removal of the primary tumor). The term metastatic PPGLs is not used in the presence of tumor invasion into surrounding organs and tissues, without the presence of distant metastases of lymphogenic or hematogenic origin. It is generally believed that about 10% of pheochromocytomas and about 40% of sympathetic paragangliomas have metastatic potential. On average, the prevalence of PPGLs with the presence of metastases is 15-20%. Risk factors for metastatic PPGLs are widely discussed in the literature, the most significant of which are groups of clinical, morphological and genetic characteristics. The review presents a discussion of such risk factors for metastatic PPGLs as age, localization and type of hormonal secretion of the tumor, the size and growth pattern of the adrenal lesion, the presence of necrosis and invasion into the vessels, the tumor capsule surrounding adipose tissue, high cellular and mitotic activity, Ki-67 index, expression of chromogranin B and S100 protein, the presence of genetic mutations of three main clusters (pseudohypoxia, kinase signaling and Wnt signaling).Over the past two decades, a number of authors have proposed various predictor factors and scales for assessing a probability of metastatic PPGLs. The review contains detailed description and comparison of sensitivity and specificity of such predictor scales as PASS, GAPP, M-GAPP, ASES and COPPS.

Indexed as

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaHumansNeoplasm MetastasisRisk Factors

Identifiers

PMID38796759
PMCPMC11145567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.